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Abstract 
Introduction.  In this pilot study the effects of vitrectomy on PO2 in the vitreous cavity in central 
retinal vein occlusion (CRVO) were investigated with a prospective, controlled, interventional 
study. 
Methods.  Six patients with CRVO in one eye and six with either macula hole or membrane 
undergoing vitrectomy were included as a control group.  An oxygen probe was inserted before 
removal of the vitreous (pre-vitrectomy) and after removal of the vitreous (post-vitrectomy). 
Oxygenation recordings (PO2) were taken in the mid-vitreous cavity and the preretinal vitreous.  
Results.  In both groups pre-vitrectomy the PO2 adjacent to the retina was significantly (p<0.05) 
less than mid-cavity: control, 15.0±5.7 vs 33.7±12.8 mmHg; CRVO, 8.1±3.5 vs 19.8±7.3 mmHg.  
Moreover the PO2 was significantly less at each site in the CRVO group compared to control. Post-
vitrectomy the PO2 was significantly greater than pre-vitrectomy at both recording sites for the 
controls (75.8±9.1 and 61.5±13.9 mmHg, pre-retinal and mid cavity, respectively) and the CRVO 
group (59.8±15.8 and 53.7±17.9, respectively).  In addition the PO2 gradient existing pre-
vitrectomy from mid-cavity to pre-retina was abolished in both groups. 
Conclusion.  PO2 is reduced in the vitreous cavity in eyes with CRVO. Vitrectomy is a method of 
increasing oxygen availability, at least in the short-term. 
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Introduction 
Central retinal vein occlusion (CRVO) is second only to diabetic retinopathy as the most frequent 
vascular cause of visual loss 1.  The exact pathogenesis is not known 2; however, the central retinal 
vein  appears to reduce in calibre as it passes through the lamina cribrosa 3. If the occlusion is 
minor, retinal ischaemia is limited, but more severe CRVO manifests as a more ischaemic type.  
Ischaemic retinal damage enhances production of vascular endothelial growth factor (VEGF) in 
the vitreous cavity 4, which in turn stimulates neovascularization of the posterior and anterior 
segment and is responsible for secondary complications such as neovascular glaucoma. 
 
Several treatments have been proposed including injections of recombinant tissue plasminogen 
activator into the vitreous or direct injection into a cannulated central vein 5.  The main surgical 
procedure over recent years has been radial optic neurotomy (RON) 6, 7, thought to be effective by 
improving central retinal vein blood flow by relieving pressure on the vein as it exits the lamina 
cribrosa.   In combination with pars plana vitrectomy, good anatomical and visual results in 
patients with non-ischaemic and ischaemic CRVO have been claimed with this approach.   
Vitrectomy may be useful by increasing oxygenation to the retina and thus reduce 
neovascularisation 8.  We hypothesise that vitreous PO2 measured in patients with CRVO is 
reduced, compared to control, and this hypoxia may be reversed post-vitrectomy by replacement of 
the vitreous humour with a physiological saline solution. 
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Methods  
 The study was undertaken with approval from the local Ethics Committee and with informed 
patient consent, in accordance with the Helsinki declaration.  Six patients with CRVO in one eye, 
were recruited into the study. As controls, six patients for either macula hole or epiretinal 
membrane removal with vitrectomy were used.  The affected eye was dilated using a mixture of 
phenylephrine 2.5% and Tropicamide 1%. Three sclerotomies were prepared; the infusion canula 
was inserted but not switched on.  
 
Flexible Licox (polarographic) O2 electrodes (Revoxode, Model CC1.SB, 0.8 mm tip diameter) 
were used in combination with a Licox CMP monitor (Integra Neurosciences). The O2 electrodes 
were calibrated at source and the O2 and temperature sensitivity stored on a card accompanying the 
probe.  The card was inserted into the monitor prior to use so that absolute values of PO2 were 
obtained.  The temperature in the eye was assumed to be 37°C and this value was set on the 
monitor setting. The oxygen probe was inserted in to the eye and oxygenation recordings were 
taken in the mid-vitreous cavity and pre-retinal vitreous inferior to the disc and away from visible 
blood vessels. The direction of the probe was slightly tangential to the retina as the recording area 
is about 5 mm behind the probe tip.  A reading in each position was taken when the monitor value 
had settled, about 3-4 minutes and in agreement with the manufactures details of a 90% response 
time of about 290 s ex vivo. Values of pulse, arterial blood pressure and arterial O2 saturation were 
also taken when recordings were taken. 
 
After the first readings, a standard three-port pars plana vitrectomy was performed in which the 
posterior hyaloid was detached and removed if required. A second set of oxygenation recordings 
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were taken post-vitrectomy, with balanced salt solution replacing the vitreous humour.  RON was 
performed in a radial fashion to avoid transecting the nerve fibres into the nasal optic disc in 
patients with CRVO. A specifically-designed micro vitreoretinal (MVR) blade was inserted to a 
depth of 2.5 mm, as described previously 6. If bleeding was observed, the infusion bottle was 
raised to stop the haemorrhage. The eyes in control patients underwent standard epiretinal 
membrane removal or macula hole surgery. Phacoemulsification was performed before vitrectomy 
if required. Post-operative follow up was conducted at 2, 4, 8 and 16 weeks. 
 
To check the zero-value reading after use, to ensure no drift in output had occurred during the 
experimental period, three O2 electrodes were placed in 50 ml Hartmann’s solution containing 10 
mM Na bisulphite to absorb dissolved O2 (PO2, 0 mmHg) and the monitor temperature sensitivity 
setting changed to the ambient value of the operating theatre.  In each case the monitor displayed 
values of 0 mmHg.  
 
Data are quoted as mean ± standard deviation.  Paired or unpaired Student’s t-tests were used to 
examine differences between data sets. The null hypothesis was rejected at p<0.05. 
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Results 
Data were obtained from six control patients (5 males, 1 female) and six with CRVO (1 male, 5 
females) and are shown in Table 1.  In one patient from each group, measurements were made only 
in the middle of the vitreous humour cavity, whereas in the remainder additional measurements 
were made adjacent to the retina. The ages of the patients ranged from 46 to 82 years of age with a 
mean of 65 years with no difference in the mean age of the two groups. The time interval of 
CRVO diagnosis to treatment was 2 to 12 months, with a mean of 8 months. With all patients the 
post-operative follow-up period ranged from 3 to 12 months, with a mean of 7 months. The 
median preoperative best-corrected visual acuity (BCVA) was 6/60 for control eyes and counting 
fingers (CF) for study eyes. The median postoperative BCVA was 6/12 for control eyes and CF for 
study eyes. None of the eyes suffered retinal or iris neovascularisation within the follow up period. 
 
Cardiovascular variables were monitored throughout the recording period to ensure that variation 
in O2 saturation or haemodynamics could not affect PO2 readings in the vitreous cavity.  In all 
patients O2 saturation was more than 98% throughout.  There were no differences in mean arterial 
blood pressure (MAPD) or heart rate (HR) between controls and patients with CRVO either pre- or 
post-vitrectomy.  In addition vitrectomy had no effect on PO2 at either site in control and CRVO 
groups. Data are shown in Table 1. 
 
In control eyes, pre-vitrectomy the mean PO2 adjacent to the retina (pre-retina) was significantly 
less than in mid-cavity, Table 1.  Figure 1A shows that in all five eyes in which paired results were 
obtained there was a PO2 gradient in the same direction between the two sites: the mean difference 
was 18.0 ± 16.0 mm Hg, but this varied between a large gradient in some, and minor in two eyes.  
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This PO2 gradient was also observed in the CRVO group with a mean value of 10.3 ± 7.8 mm Hg. 
Furthermore, at both recording sites the mean PO2 was significantly less in eyes with CRVO, 
compared to control eyes; figure 1A, table 1.  In three patients (one control, two CRVO), PO2 
measurements were also taken immediately behind the lens.  The values were not different from 
those in the mid-cavity and were not recorded in subsequent experiments so as to minimise the 
duration of the experimental procedure. 
 
Post-vitrectomy PO2 values were significantly greater than pre-vitrectomy at both recording sites 
and in both control and CRVO eyes.  Furthermore, the negative gradient of PO2 between the mid-
cavity and pre-retinal sites were abolished in both groups; in the control group there was even a 
small reversed PO2 gradient (i.e. pre-retinal PO2 > mid-cavity PO2), whilst in the CRVO group 
there was no significant gradient.  The results are also summarised in Table 1 and shown in figure 
1B.     
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Figure 1.  PO2 values in the vitreous cavity.  A:  Values pre-vitrectomy in the mid-cavity (closed 
circles) or immediately adjacent to the retina (closed squares) in control and CRVO patients.  
Mean values are shown as horizontal bars in each dot-plot.  * p<0.05 control compared to CRVO 
for the measurement sites. B shows the results after removal of the vitreous. 
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Discussion 
Intravitreal oxygen has not been measured previously in patients with CRVO, and in this pilot 
study it was reduced in eyes with CRVO compared to controls. The vitreous is in contact with the 
retina, ciliary body, lens and aqueous, all of which may provide diffusion of O2 molecules into the 
vitreous.  If the source of O2 is from the retina this is consistent with a reduced retinal blood supply 
in these patients, as detected on fluorescein angiography and Doppler studies 9. Other conditions 
displaying retinal ischaemia, namely diabetic retinopathy, are also associated with low vitreal PO2 
10-15. However, it is of note that only 2-3% of total ocular blood flow is directed to the retina 16, so 
that other sources of vitreal O2 are likely.  
 
With animal models, the PO2 in the mid-vitreous is similar to that reported here in control human 
eyes 17,18.  In these studies a vitreal PO2 gradient between the retinal and the anterior region near 
the lens was either absent, or very shallow - increasing towards the retina.  However, close to the 
lens (<1 mm) PO2 increased significantly.  With this study in human eyes a PO2 gradient was 
observed in control and CRVO eyes, but decreasing towards the retina.  A similar, small gradient, 
has also been measured between anterior and mid-vitreal spaces in human eyes 19.  Therefore, we 
hypothesise that in human eyes other fractions of ocular blood flow do indeed contribute 
significantly to vitreal O2 content, and furthermore that the vitreous may actually be an O2 source 
to the retina, especially during ischaemia.  This study could not confirm the presence of 
submillimetre PO2 gradients near to the retina: the polarographic O2 probes used in this study 
measure the average value within about 1 mm of the probe surface (sampling volume about 45 nl); 
and for ethical reasons we avoided placing the electrodes within about 1 mm of the retina.   
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After removal of the vitreous and replacement with salt solution, vitreal PO2 increased 
preoperatively, most likely due to prior bubbling the infusion bottle with air.  We do not know how 
long these higher PO2 levels persisted postoperatively, however in animal studies raised PO2 levels 
persisted for up to eight weeks 18 and in a human study PO2 levels were higher in patients re-
investigated after previous vitrectomy 19. Vitrectomy may therefore be useful as a therapy for 
ischaemic eye conditions, particularly in the retina, e.g. as a potential mechanism for the improved 
prognosis for diabetic retinopathy 20.  The lack of similar PO2 gradients post-vitrectomy suggests 
that O2 diffusion into the vitreal chamber is facilitated by replacement of the vitreal gel with saline 
solution.  This may indicate that O2 can diffuse into the chamber more readily from different 
sources such as the ciliary body, the choroid or from the anterior segment of the eye through the 
cornea 21.  
 
Visual recovery is improved in patients with CRVO after radial optic neurotomy 6, 7.  However that 
may be due to the accompanying vitrectomy on oxygenation rather than decompression of the 
central retinal vein by RON 8. Indeed RON per se causes swelling of the optic nerve head in an 
animal model, which might increase pressure on the vein in the short term 22, and this may also 
occur in humans 3.   
 
There were too few patients in this study to analyze the relationship between intravitreal PO2 and 
other surrogate measures of retinal ischaemia such as fluorescein angiography. However, because 
PO2 is reduced in CRVO patients, the need to find ways to improve their oxygenation is reinforced 
and several techniques are available. Hyperbaric oxygen breathing increases retinal and vitreal PO2 
in animals 23 and has been tried in retinal vein occlusion 24. This could be used overnight when 
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dark adaptation increases oxygen consumption 23. Perfusion of the vitreous cavity with O2-rich 
fluids either balanced salt solution or perfluorocarbon liquids may protect the retina from 
ischaemia 25,26. Relative barriers to O2 diffusion, such as silicone oil, should be avoided 27. 
 
The objective to increase oxygenation of the vitreous chamber should be offset by the caveat that 
increased PO2 is implicated in the generation of nuclear sclerotic cataracts 10,28.  Therefore, a 
balance between maintaining sufficient oxygenation to support the viability of surrounding tissues 
but preventing the development of unwanted side-effects needs to be established.  However, this 
pilot study has demonstrated reduced PO2 measurements in the vitreous cavity of patients with 
CRVO. We propose that vitrectomy may be useful in increasing vitreous PO2 thereby potentially 
improving oxygenation to the retina.  
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